A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: smallest amount (9)

Preparing your bladder and bowel for radiotherapy to the prostate or prostate bed - patient information

Description
This factsheet explains how to prepare your bladder and bowel for radiotherapy treatment to your prostate or prostate bed.
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Preparing-your-bladder-and-bowel-for-radiotherapy-to-the-prostate-or-prostate-bed-603-PIL.pdf

Welcome to the primary ciliary dyskinesia (PCD) service - patient information

Description
This self-management plan has been designed to help you record details of yourprimary ciliary dyskinesia (PCD) treatment, action plan and
Url
/Media/UHS-website-2019/Patientinformation/Respiratory/PCD-patient-self-management-plan-3330-PIL.pdf

Sativex - patient information

Description
This factsheet contains information about the medicine Sativex.
Url
/Media/UHS-website-2019/Patientinformation/Medicinestherapiesandanaesthetics/Sativex-2664-PIL.pdf

Cytarabine(SC)-Venetoclax

Description
Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Ne
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

Darolutamide

Description
Chemotherapy Protocol PROSTATE CANCER DAROLUTAMIDE Regimen • Prostate - Darolutamide Indication • Darolutamide is recomme
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Darolutamide.pdf

Afatinib Ver 1

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Regimen AFATINIB NSCLC - Afatinib Indication Trea
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AfatinibVer1.pdf

Ibrutinib (WM) (420mg)

Description
Chemotherapy Protocol Waldenström's Macroglobulinaemia (WM) Regimen Ibrutinib • WM – Ibrutinib (420mg) Indication • The treatment of adult patients with Waldenst
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-WM-420mg.pdf

InP- VTD-PACE (IV) Bortezomib (IV) Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Thalidomide

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD-PACE (IV)-BORTEZOMIB (IV)-CISPLATIN-CYCLOPHOSPHAMIDEDEXAMETHASONE-DOXORUBICIN
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/InP-VTD-PACE-IV-Bortezomib-IV-Cisplatin-Cyclophosphamide-Dexamethasone-Doxorubicin-Etoposide-Thalidomide.pdf

InP- VTD PACE (SC) Bortezomib (SC) Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Thalidomide

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD-PACE (SC)-BORTEZOMIB (SC)-CISPLATIN-CYCLOPHOSPHAMIDEDEXAMETHASONE-DOXORUBICIN
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/InP-VTD-PACE-SC-Bortezomib-SC-Cisplatin-Cyclophosphamide-Dexamethasone-Doxorubicin-Etoposide-Thalidomide.pdf

Ibrutinib

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia Regimen Ibrutinib • CLL – Ibrutinib Indication • NICE TA 429 recommends ibrutini
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Ibrutinib.pdf
211 to 220 of 701
Previous … 20 21 22 23 24 … Next